Answers are grounded in this paper and cite their sources.
Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The safety profile was favorable.
No takes yet. Share an insight, caveat, or question.
Gadelha et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: